CMPS News and Press, COMPASS Pathways Plc From 08/31/23

A retired firefighter from California is funding psychedelic retreats for firefighters to help address mental disorders they developed while on the job. Access to psychedelics in the United States is mostly limited to a small number of clinical studies, meaning that the... Read more »...

2023-08-31 12:35:49 ET More on psychedelic drugmakers Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Mind Medicine Inc. ( MNMD ) Q2 2023 Earnings Call Transcript Psychedelic Sto...

LONDON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following investor conferences: Citiȁ...

Recent scientific interest in psychedelics as alternative mental health treatments has raised questions on the application of hallucinogens in treating athletes’ mental health. Following decades of federal criminalization, we have entered an age of looser drug policies and even drug refo...

2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...

The Psychedelic Club of Denver has announced that it will hold the city’s first-ever Psychedelic Cup , an event that will see locals compete in cultivating magic mushrooms at home. Club President Jonathan Cherkoss said that the event may also be the first of its kind in the entire state. ...

2023-08-16 14:37:56 ET More on COMPASS Pathways ADS Compass Pathways: Debt Deal Secured, Cash Runway Extended COMPASS Pathways plc ( CMPS ) Q2 2023 Earnings Call Transcript Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The...

Transaction led by healthcare specialist investors, TCGX and Aisling Capital $125 million financing upfront with up to an additional $160 million tied to exercise of warrants Net proceeds from financing expected to extend cash runway into late 2025 LONDON, Aug. 16,...

A preliminary study has revealed that psilocybin, the main psychoactive agent in magic mushrooms, may have applications in migraine treatments. Researchers from Yale School of Medicine recently ran the first-ever clinical trial on the therapeutic potential of psychedelics against migraines. ...

2023-08-14 01:03:21 ET Summary COMPASS Pathways continues to make solid progress in its ambition to gain regulatory approval for COMP360 psilocybin-assisted therapy for treatment-resistant depression. The group has refined its strategy for the eventual monetization of COMP360, and...